Edition:
United States

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

6.30USD
16 Oct 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.30
Open
$6.25
Day's High
$6.30
Day's Low
$6.20
Volume
1,728
Avg. Vol
5,146
52-wk High
$7.27
52-wk Low
$5.05

Chart for

About

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies,... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $77.55
Shares Outstanding(Mil.): 12.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.52 16.83
EPS (TTM): -- -- --
ROI: -- 14.97 10.92
ROE: -- 16.23 14.52

BRIEF-Chembio Diagnostics CEO has returned to work after a medical leave of absence​

* Chembio Diagnostics Inc - president and CEO ‍John Sperzel has returned to work following a medical leave of absence​ Source text for Eikon: Further company coverage:

Oct 02 2017

BRIEF-Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test

* Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 28 2017

BRIEF-Chembio Diagnostics reports Q2 loss per share of $0.18

* Chembio Diagnostics reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Chembio Diagnostics Inc qtrly ‍net loss $0.18- SEC Filing

* Chembio Diagnostics Inc qtrly ‍net loss of $2.17 million, or $0.18 per diluted share​

Aug 09 2017

BRIEF-Chembio's DPP Zika System including the DPP Micro Reader approved by Brazil's Health Regulatory Agency

* Chembio's DPP® zika system including the DPP® micro reader approved by Brazil's Health Regulatory Agency

Jul 05 2017

BRIEF-Chembio diagnostics announces At-The-Market-Program

* Chembio Diagnostics- announced that it has established an "at--market" program through which it may offer and sell up to $21.2 million of common stock

Jun 27 2017

BRIEF-Acuta Capital Partners reports a 10.3 pct passive stake in Chembio Diagnostics

* Acuta Capital Partners LLC reports a 10.3 percent passive stake in Chembio Diagnostics Inc as of May 31, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2s26Att) Further company coverage:

Jun 12 2017

BRIEF-Chembio Diagnostics reports Q1 loss per share $0.13

* Chembio Diagnostics reports first quarter 2017 financial results

May 09 2017

Competitors

Earnings vs. Estimates